Category: Osiris Therapeutics

Avoid Osiris Therapeutics

I recommend avoiding shares of Osiris Therapeutics (OSIR). I believe the stock is meaningfully over-valued at this price, and I see potential clinical failures, the dissolution of the development partnership with Sanofi Aventis, and subsequent dilutive cash raises as catalysts to drive the shares significantly lower. Osiris Therapeutics is a stem cell company focused on…